TG Therapeutics (TGTX) reported Q1 results swung to net income Monday of $0.03 per diluted share, from a loss of $0.07 a year earlier.
Analysts polled by FactSet expected $0.17.
Total revenue for the quarter ended March 31 was $120.9 million, up from $63.5 million a year earlier.
Analysts surveyed by FactSet expected $117.9 million.
As of March 31, the company said its $276.2 million in cash, cash equivalents and investment securities on hand, combined with projected revenues of for BRIUMVI, could fund operations based on its current operating plan.
BRIUMVI is the company's ublituximab-xiiy autoimmune disorders therapy, for disorders such as relapsing mutliple sclerosis.
The company updated its full-year 2025 BRIUMVI total global revenue guidance to $575 million from its previous guidance of $540 million. Analysts polled by FactSet expect $552.9 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.